Dr. Dinan is a health services researcher by training and she specializes in using econometric and epidemiologic methodologies to analyze complex datasets. Specifically, Dr. Dinan's research involves issues related to advances in cancer care technologies, such as emerging treatments and diagnostics, and how these advances in technologies impact different cancer outcomes and experiences such as access, quality of care, cost of care, and health disparities.
Dr. Dinan has led studies funded by the National Institutes of Health, the American Cancer Society, and the Agency for Healthcare Research and Quality. She is currently leading an NCI-funded R01 study examining multi-level factors that contribute to disparities in access and adherence to oral anticancer agents for patients with kidney cancer. Dr. Dinan is also leading a study funded by the ACS to develop and validate risk prediction algorithms to inform efficient and high-quality care for long-term cancer survivors.
Areas of expertise: Health Economics, Health Policy, and Health Services Research
Education and Training
- Ph.D., University of North Carolina - Chapel Hill, 2011
- B.S., University of Virginia, 2003